Analysts’ Viewpoint
Rise in awareness and acceptance of nuclear medicine procedures are the key drivers of the global nuclear medicine market. Nuclear medicine provides accurate and early diagnosis of various medical conditions. Increase in adoption of advanced imaging technologies such as PET-CT and SPECT is expected to propel the global nuclear medicine industry growth during the forecast period. Furthermore, surge in usage of nuclear medicine procedures in the treatment of various medical conditions, such as cancer and cardiovascular diseases, is likely to bolster global nuclear medicine market size.
Increase in investment in research & development of new nuclear medicine procedures offers lucrative opportunities to market players. Companies are focusing on developing more efficient and cost-effective nuclear medicine procedures in order to increase market share.
Nuclear medicine refers to a specialized radiology field that utilizes small amounts of radioactive materials, known as radiopharmaceuticals, to examine the structure and function of organs. This imaging technique is an amalgamation of various disciplines such as chemistry, physics, mathematics, computer technology, and medicine. It is particularly useful in the early detection and treatment of diseases, such as thyroid cancer.
By analyzing the behavior of radionuclides in the body during a nuclear scan, healthcare professionals can diagnose a range of conditions, including infections, tumors, cysts, hematomas, and organ enlargement. Additionally, nuclear scans are helpful in assessing organ function and blood circulation.
Positron emission tomography (PET) is a type of nuclear medicine that uses a tracer to demonstrate the natural activity of cells, providing detailed information on organ functionality and cell damage. PET scans are often combined with three-dimensional imaging techniques, such as computed tomography (CT) or magnetic resonance imaging (MRI), to produce a more comprehensive picture of the organ.
Surge in incidence of cancer and cardiovascular diseases is one of the major drivers of the global nuclear medicine market growth. Nuclear medicine plays a critical role in the diagnosis, staging, and treatment of these diseases.
Cancer is a leading cause of death globally, and the number of new cases is expected to increase in the next few years. Nuclear medicine techniques, such as PET and SPECT, are widely used for cancer diagnosis, staging, and treatment planning. Radiopharmaceuticals are used to target cancer cells and deliver radiation therapy directly to the tumor site, reducing the risk of damage to healthy tissue.
Cardiovascular diseases, including heart disease and stroke, are also major global health concerns. Nuclear medicine techniques such as myocardial perfusion imaging (MPI) and positron emission tomography (PET) are commonly used for the diagnosis and management of cardiovascular diseases.
Aging population and increase in demand for personalized medicine are also driving the global nuclear medicine industry. Rise in the geriatric population increases the incidence of chronic diseases that require nuclear medicine interventions. Personalized medicine, which involves tailoring treatment to an individual's specific genetic and biological characteristics, relies primarily on nuclear medicine techniques for accurate diagnosis and treatment.
Overall, increase in incidence of cancer & cardiovascular diseases, aging population, and rise in demand for personalized medicine are expected to drive nuclear medicine market demand in the next few years.
Rise in awareness and acceptance of nuclear medicine procedures are the key drivers of global nuclear medicine market development. Demand for nuclear medicine procedures is expected to increase significantly, as more people become aware of the benefits of the procedures.
One of the key advantages of nuclear medicine procedures is the ability to provide accurate and early diagnosis of various medical conditions. Nuclear medicine procedures are non-invasive and use small amounts of radioactive materials to produce detailed images of the body's internal organs and tissues. These images can help healthcare professionals detect and diagnose diseases at an early stage, which can significantly improve patient outcomes.
Nuclear medicine procedures are increasingly being used in the treatment of various medical conditions, such as cancer and cardiovascular diseases. Nuclear medicine therapies use radioactive materials to target and destroy cancer cells or other abnormal cells in the body, without causing significant damage to healthy cells.
Increase in acceptance of nuclear medicine procedures as a standard part of healthcare is another key driver of the market. As healthcare professionals become more familiar with nuclear medicine procedures and their benefits, they are more likely to recommend them to patients.
In terms of type, the diagnostic nuclear medicine segment accounted for the largest global nuclear medicine market share in 2022. Diagnostic nuclear medicine involves usage of radiopharmaceuticals to diagnose various medical conditions, including cancer, heart disease, and neurological disorders. It is a non-invasive imaging technique that provides high-quality images of the body's internal organs, tissues, and bones.
The diagnostic nuclear medicine segment is driven by increase in demand for accurate and effective diagnostic procedures. Rise in prevalence of chronic diseases, such as cancer and cardiovascular diseases, and surge in demand for early disease detection and prevention are fueling the growth of the segment.
The diagnostic nuclear medicine segment is benefiting from the increasing adoption of advanced imaging technologies such as PET-CT and SPECT. These imaging technologies provide high-resolution images that aid in accurate diagnosis and treatment planning.
Based on application, the oncology segment dominated the global nuclear medicine market in 2022. Nuclear medicine plays a critical role in the diagnosis and treatment of various types of cancers, including breast cancer, lung cancer, prostate cancer, and lymphoma. Nuclear medicine is used primarily for diagnosis, staging, and treatment of cancer.
Rise in prevalence of cancer across the world and increase in demand for effective cancer treatments are driving the oncology segment. Usage of PET-CT and SPECT imaging technologies is increasing in the diagnosis and treatment of cancer. These imaging technologies are used to locate cancerous cells and monitor the effectiveness of cancer treatments.
In terms of end-user, the hospitals segment held the largest share of global nuclear medicine market value in 2022. Nuclear medicine is a medical specialty that uses radioactive substances to diagnose and treat various diseases. Hospitals are the primary end-users of nuclear medicine, where it is used for a range of diagnostic and therapeutic applications.
Hospitals have a significant demand for nuclear medicine products and services due to the large number of patients they serve. Nuclear medicine procedures are commonly used for the diagnosis and treatment of cancer, cardiovascular diseases, neurological disorders, and other medical conditions. Hospitals require a constant supply of radiopharmaceuticals, which are essential for nuclear medicine procedures.
Hospitals have the necessary infrastructure and trained personnel to perform complex nuclear medicine procedures. These have specialized departments that are dedicated to nuclear medicine, which are equipped with advanced imaging equipment such as PET-CT scanners and SPECT cameras.
Nuclear medicine is a global industry that is expected to experience significant growth in the next few years. North America is the largest market for nuclear medicine in 2022. This is ascribed to presence of advanced healthcare infrastructure, high healthcare spending, and large aging population.
Europe was the second largest market for nuclear medicine in 2022. The market in the region is driven by rise in prevalence of chronic diseases, increase in healthcare expenditure, and presence of a well-established pharmaceutical industry.
The market in Asia Pacific is expected to grow at a rapid pace during the forecast period. This is ascribed to increase in demand for advanced medical imaging technologies, rise in healthcare expenditure, and surge in prevalence of chronic diseases. Countries such as China, Japan, and India are expected to be the major markets in the region.
The market in Middle East & Africa is likely to witness moderate growth during the forecast period. This is ascribed to increase in investment in healthcare infrastructure, rise in healthcare expenditure, and surge in prevalence of chronic diseases.
Expansion of product portfolio and merger & acquisition are the key strategies adopted by prominent manufacturers to increase market share and presence. GE Healthcare, Siemens Healthineers, Philips Healthcare, Cardinal Health, Bracco Imaging S.p.A., Curium Pharma, Eckert & Ziegler, Jubilant Radiopharma, Lantheus Medical Imaging, Nordion, Inc., Advanced Accelerator Applications (AAA), IBA Radiopharma Solutions, NorthStar Medical Radioisotopes, Polatom, and Isotopia Molecular Imaging are the prominent players in the global market.
The nuclear medicine market report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2022 | US$ 5.2 Bn |
| Forecast (Value) in 2031 | US$ 11.4 Bn |
| Growth Rate (CAGR) | 9.2% |
| Forecast Period | 2023-2031 |
| Historical Data | 2017-2021 |
| Quantitative Units | US$ Mn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s five forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 5.2 Bn in 2022
It is projected to reach more than US$ 11.4 Bn by 2031
It is anticipated to grow at a CAGR of 9.2% from 2023 to 2031
Rise in prevalence of chronic diseases and development of new technologies such as PET/CT systems, SPECT/CT systems.
North America is projected to be an attractive market for companies.
GE Healthcare, Siemens Healthineers, Philips Healthcare, Cardinal Health, Bracco Imaging S.p.A., Curium Pharma, Eckert & Ziegler, Jubilant Radiopharma, Lantheus Medical Imaging, Nordion, Inc., Advanced Accelerator Applications (AAA), IBA Radiopharma Solutions, NorthStar Medical Radioisotopes, Polatom, and Isotopia Molecular Imaging.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Nuclear Medicine Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Nuclear Medicine Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Technological Advancements
5.2. List of FDA Approved Radioisotopes
5.3. No. of Nuclear Medicine Centers in Major Countries
5.4. COVID-19 Pandemic Impact on Industry
6. Global Nuclear Medicine Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017-2031
6.3.1. Diagnostic Nuclear Medicine
6.3.1.1. PECT Radiopharmaceuticals
6.3.1.2. PET Radiopharmaceuticals
6.3.2. Therapeutic Nuclear Medicine
6.3.2.1. Alpha Emitters
6.3.2.2. Beta Emitters
6.3.2.3. Brachytherapy Isotopes
6.4. Market Attractiveness Analysis, by Type
7. Global Nuclear Medicine Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017-2031
7.3.1. Cardiology
7.3.2. Neurology
7.3.3. Oncology
7.3.4. Pulmonology
7.3.5. Gastroenterology
7.3.6. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Nuclear Medicine Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017-2031
8.3.1. Hospitals
8.3.2. Diagnostic Centers
8.3.2.1. Individual Practice
8.3.2.2. Group Practice
8.3.3. Research Institutes
8.4. Market Attractiveness Analysis, by End-user
9. Global Nuclear Medicine Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Nuclear Medicine Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017-2031
10.2.1. Diagnostic Nuclear Medicine
10.2.1.1. PECT Radiopharmaceuticals
10.2.1.2. PET Radiopharmaceuticals
10.2.2. Therapeutic Nuclear Medicine
10.2.2.1. Alpha Emitters
10.2.2.2. Beta Emitters
10.2.2.3. Brachytherapy Isotopes
10.3. Market Value Forecast, by Application, 2017-2031
10.3.1. Cardiology
10.3.2. Neurology
10.3.3. Oncology
10.3.4. Pulmonology
10.3.5. Gastroenterology
10.3.6. Others
10.4. Market Value Forecast, by End-user, 2017-2031
10.4.1. Hospitals
10.4.2. Diagnostic Centers
10.4.2.1. Individual Practice
10.4.2.2. Group Practice
10.4.3. Research Institutes
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Nuclear Medicine Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017-2031
11.2.1. Diagnostic Nuclear Medicine
11.2.1.1. PECT Radiopharmaceuticals
11.2.1.2. PET Radiopharmaceuticals
11.2.2. Therapeutic Nuclear Medicine
11.2.2.1. Alpha Emitters
11.2.2.2. Beta Emitters
11.2.2.3. Brachytherapy Isotopes
11.3. Market Value Forecast, by Application, 2017-2031
11.3.1. Cardiology
11.3.2. Neurology
11.3.3. Oncology
11.3.4. Pulmonology
11.3.5. Gastroenterology
11.3.6. Others
11.4. Market Value Forecast, by End-user, 2017-2031
11.4.1. Hospitals
11.4.2. Diagnostic Centers
11.4.2.1. Individual Practice
11.4.2.2. Group Practice
11.4.3. Research Institutes
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Nuclear Medicine Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017-2031
12.2.1. Diagnostic Nuclear Medicine
12.2.1.1. PECT Radiopharmaceuticals
12.2.1.2. PET Radiopharmaceuticals
12.2.2. Therapeutic Nuclear Medicine
12.2.2.1. Alpha Emitters
12.2.2.2. Beta Emitters
12.2.2.3. Brachytherapy Isotopes
12.3. Market Value Forecast, by Application, 2017-2031
12.3.1. Cardiology
12.3.2. Neurology
12.3.3. Oncology
12.3.4. Pulmonology
12.3.5. Gastroenterology
12.3.6. Others
12.4. Market Value Forecast, by End-user, 2017-2031
12.4.1. Hospitals
12.4.2. Diagnostic Centers
12.4.2.1. Individual Practice
12.4.2.2. Group Practice
12.4.3. Research Institutes
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Nuclear Medicine Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017-2031
13.2.1. Diagnostic Nuclear Medicine
13.2.1.1. PECT Radiopharmaceuticals
13.2.1.2. PET Radiopharmaceuticals
13.2.2. Therapeutic Nuclear Medicine
13.2.2.1. Alpha Emitters
13.2.2.2. Beta Emitters
13.2.2.3. Brachytherapy Isotopes
13.3. Market Value Forecast, by Application, 2017-2031
13.3.1. Cardiology
13.3.2. Neurology
13.3.3. Oncology
13.3.4. Pulmonology
13.3.5. Gastroenterology
13.3.6. Others
13.4. Market Value Forecast, by End-user, 2017-2031
13.4.1. Hospitals
13.4.2. Diagnostic Centers
13.4.3. Research Institutes
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Nuclear Medicine Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017-2031
14.2.1. Diagnostic Nuclear Medicine
14.2.1.1. PECT Radiopharmaceuticals
14.2.1.2. PET Radiopharmaceuticals
14.2.2. Therapeutic Nuclear Medicine
14.2.2.1. Alpha Emitters
14.2.2.2. Beta Emitters
14.2.2.3. Brachytherapy Isotopes
14.3. Market Value Forecast, by Application, 2017-2031
14.3.1. Cardiology
14.3.2. Neurology
14.3.3. Oncology
14.3.4. Pulmonology
14.3.5. Gastroenterology
14.3.6. Others
14.4. Market Value Forecast, by End-user, 2017-2031
14.4.1. Hospitals
14.4.2. Diagnostic Centers
14.4.2.1. Individual Practice
14.4.2.2. Group Practice
14.4.3. Research Institutes
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2022
15.3. Company Profiles
15.3.1. GE Healthcare
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Type Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Siemens Healthineers
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Type Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Philips Healthcare
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Type Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Cardinal Health
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Type Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Bracco Imaging S.p.A.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Type Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Curium Pharma
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Type Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Eckert & Ziegler
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Type Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Jubilant Radiopharma
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Type Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Lantheus Medical Imaging
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Type Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Nordion, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Type Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Advanced Accelerator Applications (AAA)
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Type Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. IBA Radiopharma Solutions
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Type Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. NorthStar Medical Radioisotopes
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Type Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
15.3.14. Polatom
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Type Portfolio
15.3.14.3. Financial Overview
15.3.14.4. SWOT Analysis
15.3.14.5. Strategic Overview
15.3.15. Isotopia Molecular Imaging
15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.15.2. Type Portfolio
15.3.15.3. Financial Overview
15.3.15.4. SWOT Analysis
15.3.15.5. Strategic Overview
List of Table
Table 01: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 02: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 03: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 04: Global Nuclear Medicine Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 07: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 08: North America Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 09: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 11: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 12: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 13: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 15: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 16: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 17: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 19: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 20: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 23: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by Application, 2017‒2031
Table 24: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, by End-user, 2017-2031
List of Figure
Figure 01: Global Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Nuclear Medicine Market Value Share, by Type, 2022
Figure 03: Global Nuclear Medicine Market Value Share, by Application, 2022
Figure 04: Global Nuclear Medicine Market Value Share, by End-user, 2022
Figure 05: Global Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
Figure 06: Global Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
Figure 07: Global Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
Figure 08: Global Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
Figure 09: Global Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
Figure 10: Global Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
Figure 13: Global Nuclear Medicine Market Value Share Analysis, by Region, 2022 and 2031
Figure 14: Global Nuclear Medicine Market Attractiveness Analysis, by Region, 2023-2031
Figure 15: North America Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
Figure 16: North America Nuclear Medicine Market Value Share Analysis, by Country, 2022 and 2031
Figure 17: North America Nuclear Medicine Market Attractiveness Analysis, by Country, 2023-2031
Figure 18: North America Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
Figure 19: North America Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
Figure 20: North America Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
Figure 21: North America Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
Figure 22: North America Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
Figure 23: North America Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
Figure 24: Europe Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
Figure 25: Europe Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 26: Europe Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 27: Europe Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
Figure 28: Europe Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
Figure 29: Europe Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
Figure 30: Europe Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
Figure 29: Europe Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
Figure 30: Europe Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
Figure 31: Asia Pacific Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
Figure 32: Asia Pacific Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 33: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 34: Asia Pacific Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
Figure 35: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
Figure 36: Asia Pacific Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
Figure 37: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
Figure 38: Asia Pacific Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
Figure 39: Asia Pacific Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
Figure 40: Latin America Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
Figure 41: Latin America Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 42: Latin America Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 43: Latin America Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
Figure 44: Latin America Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
Figure 45: Latin America Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
Figure 46: Latin America Nuclear Medicine Market Attractiveness Analysis, by Application, 2023-2031
Figure 47: Latin America Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
Figure 48: Latin America Nuclear Medicine Market Attractiveness Analysis, End-user, 2023-2031
Figure 49: Middle East & Africa Nuclear Medicine Market Value (US$ Mn) Forecast, 2017-2031
Figure 50: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 51: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 52: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by Type, 2022 and 2031
Figure 53: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by Type, 2023-2031
Figure 54: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by Application, 2022 and 2031
Figure 55: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by Application 2023-2031
Figure 56: Middle East & Africa Nuclear Medicine Market Value Share Analysis, by End-user, 2022 and 2031
Figure 57: Middle East & Africa Nuclear Medicine Market Attractiveness Analysis, by End-user, 2023-2031
Figure 58: Global Nuclear Medicine Market Share Analysis By Company (2022)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Nuclear Medicine Market
